JOHNSON INVESTMENT COUNSEL INC - CYMABAY THERAPEUTICS INC ownership

CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 153 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.5%.

Quarter-by-quarter ownership
JOHNSON INVESTMENT COUNSEL INC ownership history of CYMABAY THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$197,100
+25.6%
18,0000.0%0.00%0.0%
Q1 2023$156,960
+39.1%
18,0000.0%0.00%0.0%
Q4 2022$112,860
+79.1%
18,0000.0%0.00%
+100.0%
Q3 2022$63,000
+18.9%
18,0000.0%0.00%0.0%
Q2 2022$53,000
-5.4%
18,0000.0%0.00%0.0%
Q1 2022$56,000
-8.2%
18,0000.0%0.00%0.0%
Q4 2021$61,000
-7.6%
18,0000.0%0.00%0.0%
Q3 2021$66,000
-15.4%
18,0000.0%0.00%0.0%
Q2 2021$78,000
-4.9%
18,0000.0%0.00%0.0%
Q1 2021$82,000
-20.4%
18,0000.0%0.00%
-50.0%
Q4 2020$103,00018,0000.00%
Other shareholders
CYMABAY THERAPEUTICS INC shareholders Q2 2023
NameSharesValueWeighting ↓
Foresite Capital Management IV, LLC 1,787,094$26,645,57214.80%
Lynx1 Capital Management LP 994,161$14,822,9419.80%
Octagon Capital Advisors LP 3,073,750$45,829,6137.04%
Saturn V Capital Management LP 1,124,459$16,765,6847.02%
Altium Capital Management LP 800,000$11,928,0006.22%
Affinity Asset Advisors, LLC 1,129,376$16,838,9964.74%
ACUTA CAPITAL PARTNERS, LLC 418,000$6,232,3804.18%
Cormorant Asset Management, LP 3,850,000$57,403,5003.35%
SILVERARC CAPITAL MANAGEMENT, LLC 590,000$8,796,9002.67%
MPM BioImpact LLC 610,770$9,106,5812.43%
View complete list of CYMABAY THERAPEUTICS INC shareholders